<DOC>
	<DOCNO>NCT00731952</DOCNO>
	<brief_summary>The purpose study find effect ( good bad ) two medication ( VELCADE Vorinostat ) patient certain type lung cancer . The study `` dose escalating '' meaning patient receive different dos medication depend enter study . Participation study last approximately 3 month include initial screen visit , visit week 3 week receive study medication , 2 additional visit around time surgery remove lung cancer tumor .</brief_summary>
	<brief_title>Phase I Study Induction Therapy With VELCADE Vorinostat Patients With Surgically Resectable Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm NSCLC ( clinical stage IB , IIA , IIB , IIIA , select IIIB ( T4N01M0 ) ) , exclusive patient MPE Planned surgical resection Age &gt; 18 year ECOG performance status 01 Patient adequate organ marrow function , define : Patient platelet count &gt; 100 x 109/L Patient WBC count &gt; 3.5 x 109/L Patient absolute neutrophil count &gt; 1.5 x 109/L Patient hemoglobin &gt; 8 gm/dl . Patients may receive transfusion , erythropoietin darbepoetin achieve hemoglobin level . Patient serum creatinine &lt; 2.0 mg/dL Patient AST &lt; 1.5 x ULN Patient bilirubin &lt; 1.5 x ULN Patient INR &lt; 1.5 x ULN Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study Exclusion Criteria Previous chemotherapy radiation therapy within 5 year enrollment . Prior history treatment know NSCLC within last 5 year &gt; 5 year still think investigator represent recurrent disease . Prior exposure either Velcade Vorinostat Prior exposure HDAC inhibitor within previous 30 day . Patients receive agent indication may enroll 30day washout period . Subject may take HDAC inhibitor trial . Patient &gt; /= Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , ECG evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Patient hypersensitivity VELCADE , boron mannitol . Patient know allergy component Vorinostat ( MK0683 ) Female subject pregnant breastfeeding . Confirm negative serum BhCG pregnancy test result obtain screening ( require postmenopausal surgically sterilized woman ) . Patient participate participate another investigational trial , receive investigational drugs/therapies within 30 day enrollment Serious medical psychiatric illness likely interfere participation clinical study . Patient history GI surgery procedure might , opinion investigator , interfere absorption swallow study drug . Subject currently take herbal remedy and/or homeopathic agent ( patient unwilling ) discontinue conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>surgically resectable</keyword>
</DOC>